Abstract
Currently approved drug eluting stents (DES) consist of a metallic scaffold and an elutable drug dispersed in a polymer matrix that conformally surrounds the struts. These primarily biostable polymers bind the drug to the stent and modulate the elution of the drug into the arterial tissue. This chapter summarizes the key requirements for polymers used in the DES, including physical properties, stability, compatibility with drugs, biocompatibility with vascular tissue and control of drug release. An in-depth analysis of polymer structure, coating design, drug-polymer morphology and drug elution profile is provided for the four currently marketed DES: CYPHER® Sirolimus- eluting Coronary Stent, Taxus® / Taxus Liberte®, XIENCE V™ / Promus® and Endeavor®. A new generation of DES is being developed using bioabsorbable polymers which degrade over time and leave behind a bare metal stent. This includes the RES TECHNOLOGY™ platform employed in the NEVO™ Sirolimus-eluting Coronary Stent which is explored with respect to polymer composition, degradation profile and drug release kinetics.
Keywords: Polymers, Eluting Stents, drug-polymer morphology, local drug delivery, biostable, bioabsorbable, drug delivery, stent, restenosis, coronary angioplasty, neointimal hyperplasia, bare metal stent, sterilization, cobalt chromium alloy, poly(butyl methacrylate), PBMA, ethylene oxide, esters, amides, anhydrides, reendothelialization, Cypher, Xience V, Promus, Endeavor, Parylene C, Sirolimus, isobutylene, styrene, oxidation, SIBS phase, PVDF-HFP, methacrylated phosphorylcholine, lauryl methacrylate, hydroxypropyl methacrylate, trimethylsilyl methacrylate, polyorthoesters, DL-lactide, glycolide, ethylene glycol
Current Pharmaceutical Design
Title: Polymers for Drug Eluting Stents
Volume: 16 Issue: 36
Author(s): Ted Parker, Vipul Dave and Robert Falotico
Affiliation:
Keywords: Polymers, Eluting Stents, drug-polymer morphology, local drug delivery, biostable, bioabsorbable, drug delivery, stent, restenosis, coronary angioplasty, neointimal hyperplasia, bare metal stent, sterilization, cobalt chromium alloy, poly(butyl methacrylate), PBMA, ethylene oxide, esters, amides, anhydrides, reendothelialization, Cypher, Xience V, Promus, Endeavor, Parylene C, Sirolimus, isobutylene, styrene, oxidation, SIBS phase, PVDF-HFP, methacrylated phosphorylcholine, lauryl methacrylate, hydroxypropyl methacrylate, trimethylsilyl methacrylate, polyorthoesters, DL-lactide, glycolide, ethylene glycol
Abstract: Currently approved drug eluting stents (DES) consist of a metallic scaffold and an elutable drug dispersed in a polymer matrix that conformally surrounds the struts. These primarily biostable polymers bind the drug to the stent and modulate the elution of the drug into the arterial tissue. This chapter summarizes the key requirements for polymers used in the DES, including physical properties, stability, compatibility with drugs, biocompatibility with vascular tissue and control of drug release. An in-depth analysis of polymer structure, coating design, drug-polymer morphology and drug elution profile is provided for the four currently marketed DES: CYPHER® Sirolimus- eluting Coronary Stent, Taxus® / Taxus Liberte®, XIENCE V™ / Promus® and Endeavor®. A new generation of DES is being developed using bioabsorbable polymers which degrade over time and leave behind a bare metal stent. This includes the RES TECHNOLOGY™ platform employed in the NEVO™ Sirolimus-eluting Coronary Stent which is explored with respect to polymer composition, degradation profile and drug release kinetics.
Export Options
About this article
Cite this article as:
Parker Ted, Dave Vipul and Falotico Robert, Polymers for Drug Eluting Stents, Current Pharmaceutical Design 2010; 16 (36) . https://dx.doi.org/10.2174/138161210794454897
DOI https://dx.doi.org/10.2174/138161210794454897 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phytoestrogens: Pharmacological and Therapeutic Perspectives
Current Drug Targets Delivery of Peptidic Gonadotropin Releasing Hormone Antagonists
Current Drug Delivery “Antisurvival” Factor Treatment for Hormone Refractory Prostate Cancer: Secondary Hormonal Ablation Using Somatostatin Analogs
Current Cancer Therapy Reviews Mitogen-activated Protein Kinase Kinase 6-fusion Protein (MAP2K6-FP) Potentiates the Anti-tumor effects of Paclitaxel in Ovarian Cancer
Anti-Cancer Agents in Medicinal Chemistry Cytotoxic and Radio-sensitizing Effects of Polyphenolic Acetates in a Human Glioma Cell Line (BMG-1)
Current Pharmaceutical Design A Novel Treatment Strategy for Sepsis and Septic Shock Based on the Interactions between Prostanoids, Nitric Oxide, and 20-Hydroxyeicosatetraenoic Acid
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry ATRA Entrapped in DSPC Liposome Enhances Anti-metastasis Effect on Lung and Liver During B16F10 Cell Line Metastasis in C57BL6 Mice
Anti-Cancer Agents in Medicinal Chemistry Solid-Supported Peptide Arrays in the Investigation of Protein-Protein and Protein-Nucleic Acid Interactions
Current Chemical Biology Inflammation and Mood Disorders: Proinflammatory Cytokines and the Pathogenesis of Depression
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Recent Patents in the Field of Radioprotector Development: Opportunities and Challenges
Recent Patents on Biotechnology Endothelial Progenitor Cells: Hope Beyond Controversy
Current Cancer Drug Targets Alkaloid-Metal Based Anticancer Agents
Current Topics in Medicinal Chemistry Blending of Polyethylenimine with a Cationic Polyurethane Greatly Enhances Both DNA Delivery Efficacy and Reduces the Overall Cytotoxicity
Current Pharmaceutical Biotechnology Tumorspheres Derived from HCC Cells are Enriched with Cancer Stem Cell-like Cells and Present High Chemoresistance Dependent on the Akt Pathway
Anti-Cancer Agents in Medicinal Chemistry ADAM9 as a Potential Target Molecule in Cancer
Current Pharmaceutical Design Mining the Dark Matter of the Cancer Proteome for Novel Biomarkers
Current Cancer Therapy Reviews Recent Developments in Nanoparticle Based Targeted Delivery of Chemotherapeutics
Current Bioactive Compounds Intestinal Dysbiosis, Gut Hyperpermeability and Bacterial Translocation: Missing Links Between Depression, Obesity and Type 2 Diabetes
Current Pharmaceutical Design Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors
Current Pharmaceutical Design Protein and Peptide Biopharmaceuticals: An Overview
Protein & Peptide Letters